One Charles Private Wealth Services LLC Takes $263,000 Position in Merck & Co., Inc. (NYSE:MRK)

One Charles Private Wealth Services LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,384 shares of the company’s stock, valued at approximately $263,000.

Several other institutional investors have also made changes to their positions in MRK. Geode Capital Management LLC raised its stake in Merck & Co., Inc. by 1.6% in the first quarter. Geode Capital Management LLC now owns 42,774,518 shares of the company’s stock valued at $3,289,283,000 after purchasing an additional 671,918 shares in the last quarter. Franklin Resources Inc. raised its stake in Merck & Co., Inc. by 20.6% in the first quarter. Franklin Resources Inc. now owns 35,455,780 shares of the company’s stock valued at $2,733,289,000 after purchasing an additional 6,063,098 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Merck & Co., Inc. by 9.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 24,733,151 shares of the company’s stock valued at $1,906,680,000 after purchasing an additional 2,063,255 shares in the last quarter. LSV Asset Management raised its stake in Merck & Co., Inc. by 47.8% in the second quarter. LSV Asset Management now owns 14,306,091 shares of the company’s stock valued at $1,112,584,000 after purchasing an additional 4,628,832 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its stake in Merck & Co., Inc. by 1.0% in the first quarter. UBS Asset Management Americas Inc. now owns 12,261,660 shares of the company’s stock valued at $945,251,000 after purchasing an additional 115,757 shares in the last quarter. 71.83% of the stock is owned by institutional investors.

Several research analysts have commented on the company. Truist Securities assumed coverage on Merck & Co., Inc. in a research note on Tuesday, July 27th. They set a “buy” rating and a $76.79 target price for the company. Argus reissued a “hold” rating on shares of Merck & Co., Inc. in a research note on Thursday, May 20th. Zacks Investment Research raised Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price for the company in a research note on Tuesday, August 24th. Morgan Stanley downgraded Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $90.00 to $85.00 in a research note on Tuesday, September 7th. Finally, SVB Leerink boosted their target price on Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $91.09.

MRK stock traded up $0.58 during trading on Wednesday, hitting $72.69. The company had a trading volume of 92,639 shares, compared to its average volume of 11,229,302. The business has a 50-day moving average of $76.68 and a 200-day moving average of $76.59. Merck & Co., Inc. has a one year low of $71.71 and a one year high of $86.30. The stock has a market cap of $184.01 billion, a PE ratio of 32.93, a PEG ratio of 2.16 and a beta of 0.41. The company has a current ratio of 1.31, a quick ratio of 1.06 and a debt-to-equity ratio of 0.72.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, July 28th. The company reported $1.31 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The business had revenue of $11.40 billion for the quarter, compared to analysts’ expectations of $11.21 billion. During the same period in the prior year, the business posted $1.37 earnings per share. Research analysts forecast that Merck & Co., Inc. will post 5.51 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be issued a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 3.58%. The ex-dividend date is Tuesday, September 14th. Merck & Co., Inc.’s payout ratio is presently 43.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.